Medronic Acid

Medronic Acid

SCHEMBL2383175

NCC(N)N.O=P(O)(O)CP(=O)(O)O.O=P(O)(O)CP(=O)(O)O.O=P(O)(O)CP(=O)(O)O.O=P(O)(O)CP(=O)(O)O.O=P(O)(O)CP(=O)(O)O

nearest known ligand 0.59

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.59
MMP2 P08253 1/20 0.59
THRB P10828 1/20 0.59
MAPK1 P28482 1/20 0.59
HSD17B10 Q99714 1/20 0.59
ANPEP P15144 6/20 0.57
ERAP2 Q6P179 1/20 0.57
OTC P00480 1/20 0.50
GABBR2 O75899 2/20 0.46
GABBR1 Q9UBS5 2/20 0.46
LAP3 P28838 4/20 0.42
ALDH1A1 P00352 2/20 0.41
GLUL P15104 1/20 0.40
ERAP1 Q9NZ08 1/20 0.39
LMNA P02545 1/20 0.38
CYP3A4 P08684 1/20 0.38
NFKB1 P19838 1/20 0.38
BLM P54132 1/20 0.38
PMP22 Q01453 1/20 0.38
GABRR1 P24046 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Phosphoric Acid SCHEMBL9014222 0.84 ANPEP (0.58) ANPEPERAP2OTCGABBR2GABBR1
Medronic Acid SCHEMBL10634361 0.83 ALDH1A1 (0.53) KDM4EMMP2THRBMAPK1HSD17B10
Medronic Acid SCHEMBL243320 0.83 ALDH1A1 (0.53) KDM4EMMP2THRBMAPK1HSD17B10
Medronic Acid SCHEMBL242935 0.83 ALDH1A1 (0.53) KDM4EMMP2THRBMAPK1HSD17B10
Medronic Acid SCHEMBL367902 0.81 KDM4E (0.77) KDM4EMMP2THRBMAPK1HSD17B10
Medronic Acid SCHEMBL5935312 0.80 KDM4E (0.56) KDM4EMMP2THRBMAPK1HSD17B10
Medronic Acid SCHEMBL242844 0.80 LAP3 (0.59) KDM4EMMP2THRBMAPK1HSD17B10
Medronic Acid SCHEMBL28647857 0.79 KDM4E (0.62) KDM4EMMP2THRBMAPK1HSD17B10
Medronic Acid SCHEMBL18066158 0.79 KDM4E (0.62) KDM4EMMP2THRBMAPK1HSD17B10
Medronic Acid SCHEMBL1921134 0.79 KDM4E (0.62) KDM4EMMP2THRBMAPK1HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10631557-B2 Preservative system for acidic beverages based on sequestrants PEPSICO, INC. (US) 2020-04-28 US disclosed
US-10421869-B2 Sol-gel coating compositions including corrosion inhibitor-encapsulated layered metal phosphates and related processes THE BOEING COMPANY (US) 2019-09-24 US disclosed
US-20180194949-A1 SOL-GEL COATING COMPOSITIONS INCLUDING CORROSION INHIBITOR-ENCAPSULATED LAYERED METAL PHOSPHATES AND RELATED PROCESSES THE BOEING COMPANY 2018-07-12 US disclosed
US-20170164642-A1 Preservative System For Acidic Beverages Based On Sequestrants PEPSICO, INC. 2017-06-15 US disclosed
US-8021813-B2 Electrostatic-image-developing toner, method of producing the same, electrostatic image developer, image forming method and image forming apparatus FUJI XEROX CO., LTD. (JP) 2011-09-20 US disclosed
US-20090274972-A1 ELECTROSTATIC-IMAGE-DEVELOPING TONER, METHOD OF PRODUCING THE SAME, ELECTROSTATIC IMAGE DEVELOPER, IMAGE FORMING METHOD AND IMAGE FORMING APPARATUS FUJI XEROX CO., LTD. (JP) 2009-11-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090274972-A1 ELECTROSTATIC-IMAGE-DEVELOPING TONER, METHOD OF PRODUCING THE SAME, ELECTROSTATIC IMAGE DEVELOPER, IMAGE FORMING METHOD AND IMAGE FORMING APPARATUS PPIP5K2, PHOSPHO1, CASR KDM4E 3753/4885MMP2 4805/4885THRB 3568/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.